CLN2 Antibody (G-3): sc-393961
- CLN2 Antibody (G-3) is a mouse monoclonal IgG2a κ CLN2 antibody, cited in 3 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 504-531 near the C-terminus of CLN2 of rat origin
- CLN2 Antibody (G-3) is recommended for detection of CLN2 of mouse, rat and human origin by WB, IP, IF and ELISA
- Anti-CLN2 Antibody (G-3) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgG2a BP-HRP is the preferred secondary detection reagent for CLN2 Antibody (G-3) for WB applications. This reagent is now offered in a bundle with CLN2 Antibody (G-3) (see ordering information below).
QUICK LINKS
CLN2 Antibody (G-3) is a mouse monoclonal IgG2a kappa light chain antibody that detects CLN2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CLN2 (G-3) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CLN2, also known as Tripeptidyl peptidase I (TTP-I), is a vital lysosomal aminopeptidase that plays a significant role in protein degradation within lysosomes. CLN2′s primary function involves sequential removal of tripeptides from small polypeptides, which is essential for proper turnover of cellular proteins and maintenance of cellular homeostasis. A deficiency in CLN2 can lead to severe neurodegenerative disorders, highlighting CLN2′s importance in cellular health and function. Additionally, CLN2′s proenzyme form undergoes conversion to its active form with help from other proteases and can autoactivate in acidic conditions, which is crucial for enzymatic activity in the lysosomal environment.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CLN2 Antibody (G-3) References:
- Maturation of human tripeptidyl-peptidase I in vitro. | Golabek, AA., et al. 2004. J Biol Chem. 279: 31058-67. PMID: 15143070
- Glycosaminoglycans modulate activation, activity, and stability of tripeptidyl-peptidase I in vitro and in vivo. | Golabek, AA., et al. 2005. J Biol Chem. 280: 7550-61. PMID: 15582991
- Ser475, Glu272, Asp276, Asp327, and Asp360 are involved in catalytic activity of human tripeptidyl-peptidase I. | Walus, M., et al. 2005. FEBS Lett. 579: 1383-8. PMID: 15733845
- Palmitoyl Protein Thioesterase1 (PPT1) and Tripeptidyl Peptidase-I (TPP-I) are expressed in the human saliva. A reliable and non-invasive source for the diagnosis of infantile (CLN1) and late infantile (CLN2) neuronal ceroid lipofuscinoses. | Kohan, R., et al. 2005. Clin Biochem. 38: 492-4. PMID: 15820783
- AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. | Sondhi, D., et al. 2005. Gene Ther. 12: 1618-32. PMID: 16052206
- Catalytic residues and substrate specificity of recombinant human tripeptidyl peptidase I (CLN2). | Oyama, H., et al. 2005. J Biochem. 138: 127-34. PMID: 16091586
- The neuronal ceroid-lipofuscinoses. | Bennett, MJ. and Rakheja, D. 2013. Dev Disabil Res Rev. 17: 254-9. PMID: 23798013
- Karyopherin Msn5 is involved in a novel mechanism controlling the cellular level of cell cycle regulators Cln2 and Swi5. | Quilis, I., et al. 2019. Cell Cycle. 18: 580-595. PMID: 30739521
- Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease. | Kovacs, KD., et al. 2020. Ophthalmol Retina. 4: 728-736. PMID: 32146219
- Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease. | De, BP., et al. 2023. Hum Gene Ther. 34: 905-916. PMID: 37624739
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CLN2 Antibody (G-3) | sc-393961 | 200 µg/ml | $322.00 | |||
CLN2 Antibody (G-3): m-IgG2a BP-HRP Bundle | sc-545970 | 200 µg Ab; 10 µg BP | $361.00 | |||
CLN2 Antibody (G-3) AC | sc-393961 AC | 500 µg/ml, 25% agarose | $424.00 | |||
CLN2 Antibody (G-3) HRP | sc-393961 HRP | 200 µg/ml | $322.00 | |||
CLN2 Antibody (G-3) FITC | sc-393961 FITC | 200 µg/ml | $336.00 | |||
CLN2 Antibody (G-3) PE | sc-393961 PE | 200 µg/ml | $349.00 | |||
CLN2 Antibody (G-3) Alexa Fluor® 488 | sc-393961 AF488 | 200 µg/ml | $364.00 | |||
CLN2 Antibody (G-3) Alexa Fluor® 546 | sc-393961 AF546 | 200 µg/ml | $364.00 | |||
CLN2 Antibody (G-3) Alexa Fluor® 594 | sc-393961 AF594 | 200 µg/ml | $364.00 | |||
CLN2 Antibody (G-3) Alexa Fluor® 647 | sc-393961 AF647 | 200 µg/ml | $364.00 | |||
CLN2 Antibody (G-3) Alexa Fluor® 680 | sc-393961 AF680 | 200 µg/ml | $364.00 | |||
CLN2 Antibody (G-3) Alexa Fluor® 790 | sc-393961 AF790 | 200 µg/ml | $364.00 | |||
CLN2 (G-3) Neutralizing Peptide | sc-393961 P | 100 µg/0.5 ml | $69.00 |